E-LIB Suche - Ergebnisse für: Flinn, I. W.

1

ZUMA‐24: A PHASE 2, OPEN‐LABEL STUDY OF AXICABTAGENE CILOLE..:

Leslie, L. ; Tees, M. ; Flinn, I. W....
Hematological Oncology. 41 (2023) S2 - p. 843-845 , 2023

Link: https://doi.org/10.1002/..

2

Ibrutinib (Ibr) dose modification for management of early c..:

Tedeschi, A. ; Ahn, I. E. ; Fraser, G. A. M....
Hematological Oncology. 41 (2023) S2 - p. 461-463 , 2023

Link: https://doi.org/10.1002/..

3

A phase 2 study of zanubrutinib in previously treated B‐cel..:

Shadman, M. ; Burke, J. M. ; Zafar, S. F....
Hematological Oncology. 41 (2023) S2 - p. 469-471 , 2023

Link: https://doi.org/10.1002/..

4

ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF ..:

Westin, J. ; Jacobson, C. A. ; Chavez, J. C....
Hematological Oncology. 41 (2023) S2 - p. 171-173 , 2023

Link: https://doi.org/10.1002/..

5

Updated follow‐up of BELLWAVE‐001: an open‐label, single‐ar..:

Eradat, H. ; Woyach, J. ; Flinn, I. W....
Hematological Oncology. 41 (2023) S2 - p. 565-567 , 2023

Link: https://doi.org/10.1002/..

6

Outpatient administration of mosunetuzumab in US community ..:

Flinn, I. W. ; Sharman, J. ; Liu, S....
Hematological Oncology. 41 (2023) S2 - p. 383-385 , 2023

Link: https://doi.org/10.1002/..

7

RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES ..:

Rebaud, L. ; Capobianco, N. ; Spottiswoode, B....
Hematological Oncology. 41 (2023) S2 - p. 94-95 , 2023

Link: https://doi.org/10.1002/..

8

ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN..:

Shadman, M. ; Munir, T. ; Roback, T....
Hematological Oncology. 41 (2023) S2 - p. 235-238 , 2023

Link: https://doi.org/10.1002/..

9

ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTA..:

Flinn, I. W. ; Jacobson, C. A. ; Nastoupil, L. J....
Hematological Oncology. 41 (2023) S2 - p. 853-855 , 2023

Link: https://doi.org/10.1002/..

10

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIEN..:

Sallman, D. A. ; Al Malki, M. M. ; Asch, A. S....
HemaSphere. 6 (2022) - p. 67-68 , 2022

Link: https://doi.org/10.1097/..

11

P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PAT..:

Wang, M. L. ; Munoz, J. ; Goy, A....
HemaSphere. 6 (2022) - p. 1007-1008 , 2022

Link: https://doi.org/10.1097/..

12

P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFE..:

Hernandez-Ilizaliturri, F. J. ; Kuruvilla, J. ; Christian, B. A....
HemaSphere. 6 (2022) - p. 1039-1040 , 2022

Link: https://doi.org/10.1097/..

13

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (..:

Shadman, M. ; Flinn, I. W. ; Kingsley, E. C....
HemaSphere. 6 (2022) - p. 1769-1770 , 2022

Link: https://doi.org/10.1097/..

14

P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUD..:

Vorobyev, V. ; Yoon, D. H. ; Kaźmierczak, M....
HemaSphere. 6 (2022) - p. 1013-1014 , 2022

Link: https://doi.org/10.1097/..

15

P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF ..:

Woyach, J. ; Flinn, I. W. ; Awan, F. T....
HemaSphere. 6 (2022) - p. 578-579 , 2022

Link: https://doi.org/10.1097/..